Source:http://linkedlifedata.com/resource/pubmed/id/17126951
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2007-2-19
|
pubmed:abstractText |
Vinorelbine is a moderate vesicant that is well known to cause local venous toxicity such as drug induced-phlebitis. We conducted a prospective randomized trial to determine whether a 1-min bolus injection (1 min bolus) of vinorelbine reduced the incidence of local venous toxicity compared with a 6-min drip infusion (6 min infusion). Non-small cell lung cancer patients who were to receive chemotherapy containing vinorelbine were randomly assigned to receive either 6 min infusion or 1 min bolus of the drug. All infusions were administered through a peripheral vein. Local venous toxicity was evaluated at each infusion up to two cycles. Eighty-three patients were randomized into the study and 81 of them assessable for analysis. One hundred thirty-eight infusions to 40 patients in 6 min infusion and 135 infusions to 41 patients in 1 min bolus were delivered. Vinorelbine induced-local venous toxicity was observed in 33% of patients in 6 min infusion and 24% in 1 min bolus. There was no statistically significant difference between the two arms (P=0.41). The incidence of local venous toxicity per infusions was 16% (22 of 138 infusions) in 6 min infusion and 11% (15 of 135 infusions) in 1 min bolus (P=0.47). No severe local venous toxicity was seen in either arm. In this study, the administration of in 1 min bolus of vinorelbine did not significantly reduce the incidence of local venous toxicity compared with 6 min infusion. Further studies for the control of local venous toxicity of vinorelbine are warranted.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0169-5002
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
337-41
|
pubmed:meshHeading |
pubmed-meshheading:17126951-Adult,
pubmed-meshheading:17126951-Aged,
pubmed-meshheading:17126951-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:17126951-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:17126951-Female,
pubmed-meshheading:17126951-Humans,
pubmed-meshheading:17126951-Incidence,
pubmed-meshheading:17126951-Infusions, Intravenous,
pubmed-meshheading:17126951-Injections, Intravenous,
pubmed-meshheading:17126951-Logistic Models,
pubmed-meshheading:17126951-Low Back Pain,
pubmed-meshheading:17126951-Lung Neoplasms,
pubmed-meshheading:17126951-Male,
pubmed-meshheading:17126951-Middle Aged,
pubmed-meshheading:17126951-Multivariate Analysis,
pubmed-meshheading:17126951-Phlebitis,
pubmed-meshheading:17126951-Vinblastine
|
pubmed:year |
2007
|
pubmed:articleTitle |
Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.
|
pubmed:affiliation |
Division of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. kyoh@east.ncc.go.jp <kyoh@east.ncc.go.jp>
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|